

ORAL ADMINISTRATION OF SOR102 DELIVERS ANTI-TNF/IL-23 ACTIVITY DIRECTLY TO COLONIC TISSUE AND DRIVES CLINICAL AND PHARMACODYNAMIC RESPONSES IN ULCERATIVE COLITIS PATIENTS

Pamela Wedel

UEG Week Berlin 2025

Poster

IBD

October 7, 2025

SOR102, an oral bispecific anti-TNF α /anti-IL-23 antibody, demonstrated dose-dependent colonic tissue distribution with strong correlation between tissue drug levels, pharmacodynamic responses, and clinical improvement in patients with ulcerative colitis in a Phase 1b trial.

KEY POINTS

- In the 810mg twice-daily arm, SOR102 showed higher rates of clinical response and symptomatic remission compared to placebo, with greater reductions in Mayo scores and UC-100 scores.
- Median colonic tissue concentrations of SOR102 monomers were 20-35 times higher with twice-daily dosing compared to once-daily dosing, with minimal systemic exposure (one patient had detectable serum levels below 135.2 ng/ml).
- The twice-daily arm demonstrated reduced colonic tissue levels of multiple inflammatory cytokines (IL-1 β , IL-6, TNF α , IFN γ , IL-17A, IL-10) and gene expression changes indicating reduced myeloid and lymphocyte inflammation with upregulation of cellular repair mechanisms.
- High micromolar levels of active SOR102 monomers in feces and low intact drug levels confirmed efficient cleavage by the trypsin-labile linker and maintained TNF/IL-23 binding activity throughout the gastrointestinal tract.
- This material is most relevant for clinicians and researchers interested in novel oral therapies for inflammatory bowel disease and mechanisms of targeted intestinal drug delivery.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/4ce127d4-a813-11f0-97aa-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.